Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019 Mar 7, 2019
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis Feb 25, 2019
Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City Feb 20, 2019
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome Jan 22, 2019
Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome Jan 21, 2019
Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco Dec 19, 2018
Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development Nov 8, 2018
